Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.
COVID-19
Massachusetts
interrupted time-series
naloxone availability
opioid overdose deaths
racial and ethnic disparities
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
12
01
2023
accepted:
07
07
2023
medline:
6
11
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
The onset of the coronavirus disease 2019 (COVID-19) pandemic was associated with a surge in opioid overdose deaths in Massachusetts, particularly affecting racial and ethnic minority communities. We aimed to compare the impact of the pandemic on opioid overdose fatalities and naloxone distribution from community-based programs across racial and ethnic groups in Massachusetts. Interrupted time-series. Opioid overdose deaths (OODs) among non-Hispanic White, non-Hispanic Black, Hispanic and non-Hispanic other race people in Massachusetts, USA (January 2016 to June 2021). Rate of OODs per 100 000 people, rate of naloxone kits distributed per 100 000 people and ratio of naloxone kits per opioid overdose death as a measure of naloxone availability. We applied five imputation strategies using complete data in different periods to account for missingness of race and ethnicity for naloxone data. Before COVID-19 (January 2016 to February 2020), the rate of OODs declined among non-Hispanic White people [0.2% monthly reduction (95% confidence interval = 0.0-0.4%)], yet was relatively constant among all other population groups. The rate of naloxone kits increased across all groups (0.8-1.2% monthly increase) and the ratio of naloxone kits per OOD death among non-Hispanic White was 1.1% (0.8-1.4%) and among Hispanic people was 1.0% (0.2-1.8%). After the onset of the pandemic (March 2020+), non-Hispanic Black people experienced an immediate increase in the rate of OODs [63.6% (16.4-130%)], whereas rates among other groups remained similar. Trends in naloxone rescue kit distribution did not substantively change among any groups, and the ratio of naloxone kits per OOD death for non-Hispanic Black people did not compensate for the surge in OODs deaths in this group. With the onset of the COVID-19 pandemic, there was a surge in opioid overdose deaths among non-Hispanic Black people in Massachusetts, USA with no compensatory increase in naloxone rescue kit distribution. For non-Hispanic White and Hispanic people, opioid overdose deaths remained stable and naloxone kit distribution continued to increase.
Sections du résumé
BACKGROUND AND AIMS
The onset of the coronavirus disease 2019 (COVID-19) pandemic was associated with a surge in opioid overdose deaths in Massachusetts, particularly affecting racial and ethnic minority communities. We aimed to compare the impact of the pandemic on opioid overdose fatalities and naloxone distribution from community-based programs across racial and ethnic groups in Massachusetts.
DESIGN
Interrupted time-series.
SETTING AND CASES
Opioid overdose deaths (OODs) among non-Hispanic White, non-Hispanic Black, Hispanic and non-Hispanic other race people in Massachusetts, USA (January 2016 to June 2021).
MEASUREMENTS
Rate of OODs per 100 000 people, rate of naloxone kits distributed per 100 000 people and ratio of naloxone kits per opioid overdose death as a measure of naloxone availability. We applied five imputation strategies using complete data in different periods to account for missingness of race and ethnicity for naloxone data.
FINDINGS
Before COVID-19 (January 2016 to February 2020), the rate of OODs declined among non-Hispanic White people [0.2% monthly reduction (95% confidence interval = 0.0-0.4%)], yet was relatively constant among all other population groups. The rate of naloxone kits increased across all groups (0.8-1.2% monthly increase) and the ratio of naloxone kits per OOD death among non-Hispanic White was 1.1% (0.8-1.4%) and among Hispanic people was 1.0% (0.2-1.8%). After the onset of the pandemic (March 2020+), non-Hispanic Black people experienced an immediate increase in the rate of OODs [63.6% (16.4-130%)], whereas rates among other groups remained similar. Trends in naloxone rescue kit distribution did not substantively change among any groups, and the ratio of naloxone kits per OOD death for non-Hispanic Black people did not compensate for the surge in OODs deaths in this group.
CONCLUSIONS
With the onset of the COVID-19 pandemic, there was a surge in opioid overdose deaths among non-Hispanic Black people in Massachusetts, USA with no compensatory increase in naloxone rescue kit distribution. For non-Hispanic White and Hispanic people, opioid overdose deaths remained stable and naloxone kit distribution continued to increase.
Substances chimiques
Analgesics, Opioid
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2413-2423Subventions
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NCIPC CDC HHS
ID : R01 CE002999
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA047408
Pays : United States
Informations de copyright
© 2023 Society for the Study of Addiction.
Références
Imtiaz S, Nafeh F, Russell C, Ali F, Elton-Marshall T, Rehm J. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Subst Abuse Treat Prev Policy. 2021;16:1-14.
Roberts A, Rogers J, Mason R, Siriwardena AN, Hogue T, Whitley GA, et al. Alcohol and other substance use during the COVID-19 pandemic: a systematic review. Drug Alcohol Depend. 2021;229:109150.
National Vital Statistics System. Provisional drug overdose death counts. 2023. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed 12 October 2022.
National Center for Health Statistics, Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020-but are still up 15%. 2022. Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm. Accessed 12 October 2022.
Khatri UG, Perrone J. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 2020;14:e6-e7.
Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Am College Phys. 2020;173:57-58.
Linas BP, Savinkina A, Barbosa C, Mueller PP, Cerdá M, Keyes K, et al. A clash of epidemics: impact of the COVID-19 pandemic response on opioid overdose. J Subst Abuse Treat. 2021;120:108158.
Yancy CW. COVID-19 and African Americans. JAMA. 2020;323:1891-1892.
Millett GA, Jones AT, Benkeser D, Baral S, Mercer L, Beyrer C, et al. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020;47:37-44.
Khatri UG, Pizzicato LN, Viner K, Bobyock E, Sun M, Meisel ZF, et al. Racial/ethnic disparities in unintentional fatal and nonfatal emergency medical services-attended opioid overdoses during the COVID-19 pandemic in Philadelphia. JAMA Netw Open. 2021;4:e2034878.
Friedman JR, Hansen H. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79:379-381.
Kariisa M, Seth P, Jones CM. Increases in disparities in US drug overdose deaths by race and ethnicity: opportunities for clinicians and health systems. JAMA. 2022;328:421-422.
Massachusetts Department of Public Health. Opioid-related overdose deaths, all intents, MA residents-demographic data highlights. 2021. Available at: https://www.mass.gov/doc/opioid-related-overdose-deaths-demographics-november-2021/download. Accessed 12 October 2022.
Larochelle MR, Slavova S, Root ED, Feaster DJ, Ward PJ, Selk SC, et al. Disparities in opioid overdose death trends by race/ethnicity, 2018-2019, from the HEALing communities study. Am J Public Health. 2021;111:1851-1854.
Collins AB, Ndoye CD, Arene-Morley D, Marshall BD. Addressing co-occurring public health emergencies: the importance of naloxone distribution in the era of COVID-19. Int J Drug Policy. 2020;83:102872.
O'Donoghue AL, Biswas N, Dechen T, Anderson TS, Talmor N, Punnamaraju A, et al. Trends in filled naloxone prescriptions before and during the COVID-19 pandemic in the United States. JAMA Health Forum. 2021;2:e210393.
Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Linas BP, et al. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts. Drug Alcohol Depend. 2022;241:109668.
Ong AR, Lee S, Bonar EE. Understanding disparities in access to naloxone among people who inject drugs in Southeast Michigan using respondent driven sampling. Drug Alcohol Depend. 2020;206:107743.
Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The naloxone delivery cascade: identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021;225:108759.
Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, et al. Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19. J Subst Abuse Treat. 2022;132:108648.
Massachusetts Department of Public Health. Injury surveillance program. 2022. Available at: https://www.mass.gov/injury-surveillance-program. Accessed 12 October 2022.
Zang X, Macmadu A, Krieger MS, Behrends CN, Green TC, Morgan JR, et al. Targeting community-based naloxone distribution using opioid overdose death rates: a descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. Int J Drug Policy. 2021;98:103435.
United States Census Bureau. Explore census data. United States Census Bureau. Suitland, MD. Available at: https://data.census.gov/cedsci/. Accessed 12 October 2022.
Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, et al. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: a mixed methods study of syringe services program perspectives. Int J Drug Policy. 2022;109:103825.
Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, et al. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. Drug Alcohol Depend. 2022;232:109323.
Bird SM, Parmar MK, Strang J. Take-home naloxone to prevent fatalities from opiate-overdose: protocol for Scotland's public health policy evaluation, and a new measure to assess impact. Drugs. 2015;22:66-76.
Beard E, Marsden J, Brown J, Tombor I, Stapleton J, Michie S, et al. Understanding and using time series analyses in addiction research. Addiction. 2019;114:1866-1884.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria; 2022. Available at: https://www.R-project.org/. Accessed 12 October 2022.
Zeileis A, Hothorn T. Diagnostic checking in regression relationships. R News; 2002. Available at: https://CRAN.R-project.org/doc/Rnews/. Accessed 12 October 2022.
Venables WN, Ripley BD. Modern Applied Statistics with S. New York, NY: Springer; 2002.
Dominici F, McDermott A, Zeger SL, Samet JM. Airborne particulate matter and mortality: timescale effects in four US cities. Am J Epidemiol. 2003;157:1055-1065.
Nerenz DR, McFadden B, Ulmer C. Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement Washington, DC: National Academies Press; 2009.
Friedman J, Hansen H, Bluthenthal RN, Harawa N, Jordan A, Beletsky L. Growing racial/ethnic disparities in overdose mortality before and during the COVID-19 pandemic in California. Prev Med. 2021;153:106845.
Mistler CB, Sullivan MC, Copenhaver MM, Meyer JP, Roth AM, Shenoi SV, et al. Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. J Subst Abuse Treat. 2021;129:108387.
Bennett AS, Townsend T, Elliott L. The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months. Int J Drug Policy. 2022;101:103554.
Frueh L, Collins AB, Newman R, Barnett NP, Rich JD, Clark MA, et al. Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation. Harm Reduct J. 2023;20:14.
Aponte-Melendez Y, Mateu-Gelabert P, Fong C, Eckhardt B, Kapadia S, Marks K. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm Reduct J. 2021;18:1-12.
Netherland J, Hansen H. White opioids: pharmaceutical race and the war on drugs that wasn’t. BioSocieties. 2017;12:217-238.
Hughto JM, Gordon LK, Stopka TJ, Case P, Palacios WR, Tapper A, et al. Understanding opioid overdose risk and response preparedness among people who use cocaine and other drugs: mixed-methods findings from a large, multi-city study. Subst Abuse. 2022;43:465-478.
Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. J Clin Epidemiol. 2011;64:1252-1261.
De P, Cox J, Boivin JF, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102:1730-1739.
Johnson RA, Gerstein DR, Patch A III, Cerbone FG, Brown J. HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristics. Addiction 2002;97:1011-1024.
Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:1-11.
Moustaqim-Barrette A, Papamihali K, Mamdani Z, Williams S, Buxton JA. Accessing take-home naloxone in British Columbia and the role of community pharmacies: results from the analysis of administrative data. PLOS ONE. 2020;15:e0238618.